Leading research progress and prospect of antibody-drug conjugate in pancreatic cancer in 2022

doi:10.19401/j.cnki.1007-3639.2023.03.006

Abstract

Abstract:

Pancreatic cancer is a type of malignant tumor with high incidence and low survival rate. It is urgent to develop novel and efficient therapeutic means for patients lacking surgical indications and patients with poor effects of radiotherapy and chemotherapy. In recent years, antibody-drug conjugate (ADC) has become hot because of their high selectivity and anti-tumor activity. ADC has achieved some results in the treatment of pancreatic cancer, but still face many challenges. This article provided a brief review of the latest developments of ADC in pancreatic cancer in 2022.

Key words: Antibody-drug conjugate, Pancreatic cancer, Clinical research

CLC Number:

R735.9

ZENG Cheng, ZHANG Jian. Leading research progress and prospect of antibody-drug conjugate in pancreatic cancer in 2022[J]. China Oncology, 2023, 33(3): 235-240.

References 21

[1]	CABASAG C J, FERLAY J, LAVERSANNE M, et al. Pancreatic cancer: an increasing global public health concern[J]. Gut, 2022, 71(8): 1686-1687.
[2]	HOSEIN A N, BREKKEN R A, MAITRA A. Pancreatic cancer stroma: an update on therapeutic targeting strategies[J]. Nat Rev Gastroenterol Hepatol, 2020, 17(8): 487-505. doi: 10.1038/s41575-020-0300-1 pmid: 32393771
[3]	CHAU C H, STEEG P S, FIGG W D. Antibody-drug conjugates for cancer[J]. Lancet, 2019, 394(10200): 793-804. doi: S0140-6736(19)31774-X pmid: 31478503
[4]	QI C S, GONG J F, LI J, et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results[J]. Nat Med, 2022, 28(6): 1189-1198. doi: 10.1038/s41591-022-01800-8 pmid: 35534566
[5]	KYUNO D, TAKASAWA A, TAKASAWA K, et al. Claudin-18.2 as a therapeutic target in cancers: cumulative findings from basic research and clinical trials[J]. Tissue Barriers, 2022, 10(1): 1967080.
[6]	XU R H, WEI X L, ZHANG D S, et al. A phase 1a dose-escalation, multicenter trial of anti-claudin 18.2 antibody drug conjugate CMG901 in patients with resistant/refractory solid tumors[J]. J Clin Oncol, 2023, 41(4_suppl): 352.
[7]	CAZES A, BETANCOURT O, ESPARZA E, et al. A MET targeting antibody-drug conjugate overcomes gemcitabine resistance in pancreatic cancer[J]. Clin Cancer Res, 2021, 27(7): 2100-2110. doi: 10.1158/1078-0432.CCR-20-3210 pmid: 33451980
[8]	JIN Y B, ZHANG Z H, ZOU S Y, et al. A novel c-MET-targeting antibody-drug conjugate for pancreatic cancer[J]. Front Oncol, 2021, 11: 634881.
[9]	GYMNOPOULOS M, BETANCOURT O, BLOT V, et al. TR1801-ADC: a highly potent cMet antibody-drug conjugate with high activity in patient-derived xenograft models of solid tumors[J]. Mol Oncol, 2020, 14(1): 54-68. doi: 10.1002/1878-0261.12600 pmid: 31736230
[10]	NAKANO T. Systemic treatment of malignant pleural mesothelioma[J]. Gan To Kagaku Ryoho, 2017, 44(13): 2041-2047.
[11]	HASSAN R, BLUMENSCHEIN G R Jr, MOORE K N, et al. First-in-human, multicenter, phase I dose-escalation and expansion study of anti-mesothelin antibody-drug conjugate anetumab ravtansine in advanced or metastatic solid tumors[J]. J Clin Oncol, 2020, 38(16): 1824-1835. doi: 10.1200/JCO.19.02085 pmid: 32213105
[12]	SPILIOPOULOU P, KASI A, ABUSHAHIN L I, et al. Phase Ib study of anetumab ravtansive in combination with immunotherapy or immunotherapy plus chemotherapy in mesothelin-enriched advanced pancreatic adenocarcinoma: NCI10208[J]. J Clin Oncol, 2022, 40(16_suppl): 4136. doi: 10.1200/JCO.2022.40.16_suppl.4136
[13]	CUBAS R, ZHANG S, LI M, et al. Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway[J]. Mol Cancer, 2010, 9: 253. doi: 10.1186/1476-4598-9-253 pmid: 20858281
[14]	CARDILLO T M, GOVINDAN S V, SHARKEY R M, et al. Sacituzumab govitecan (IMMU-132), an anti-trop-2/SN-38 antibody-drug conjugate: characterization and efficacy in pancreatic, gastric, and other cancers[J]. Bioconjug Chem, 2015, 26(5): 919-931. doi: 10.1021/acs.bioconjchem.5b00223
[15]	BARDIA A, MESSERSMITH W A, KIO E A, et al. Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase Ⅰ/Ⅱ IMMU-132-01 basket trial[J]. Ann Oncol, 2021, 32(6): 746-756. doi: 10.1016/j.annonc.2021.03.005
[16]	YANG M C, SHIA C S, LI W F, et al. Preclinical studies of OBI-999: a novel globo H-targeting antibody-drug conjugate[J]. Mol Cancer Ther, 2021, 20(6): 1121-1132. doi: 10.1158/1535-7163.MCT-20-0763
[17]	HAN Z W, LYV Z W, CUI B, et al. The old CEACAMs find their new role in tumor immunotherapy[J]. Invest New Drugs, 2020, 38(6): 1888-1898. doi: 10.1007/s10637-020-00955-w
[18]	DERY K J, GAUR S, GENCHEVA M, et al. Mechanistic control of carcinoembryonic antigen-related cell adhesion molecule-1 (CEACAM1) splice isoforms by the heterogeneous nuclear ribonuclear proteins hnRNP L, hnRNP A1, and hnRNP M[J]. J Biol Chem, 2011, 286(18): 16039-16051. doi: 10.1074/jbc.M110.204057 pmid: 21398516
[19]	TIAN B M, WONG W Y, UGER M D, et al. Development and characterization of a camelid single domain antibody-urease conjugate that targets vascular endothelial growth factor receptor 2[J]. Front Immunol, 2017, 8: 956. doi: 10.3389/fimmu.2017.00956 pmid: 28871252
[20]	TIAN B, WONG W Y, HEGMANN E, et al. Production and characterization of a camelid single domain antibody-urease enzyme conjugate for the treatment of cancer[J]. Bioconjugate Chem, 2015, 26(6): 1144-1155. doi: 10.1021/acs.bioconjchem.5b00237 pmid: 25938892
[21]	SINGH C S B, EYFORD B A, ABRAHAM T, et al. Discovery of a highly conserved peptide in the iron transporter melanotransferrin that traverses an intact blood brain barrier and localizes in neural cells[J]. Front Neurosci, 2021, 15: 596976.